Olaratumab: a platelet-derived growth factor receptor-α-blocking antibody for the treatment of soft tissue sarcoma.
- Published in:
- Clinical Pharmacology, 2017, v. 9, p. 159, doi. 10.2147/CPAA.S130178
- By:
- Publication type:
- Article
Works by Pender, Alexandra
Results: 11
1
2
Report from the World Conference on Lung Cancer (WCLC): Improving survival in lung cancer.
- Published in:
- 2018
- By:
- Publication type:
- Proceeding
3
Improved uptake and survival with systemic treatments for metastatic non-small cell lung cancer: younger versus older adults.
- Published in:
- BMC Cancer, 2023, v. 23, n. 1, p. 1, doi. 10.1186/s12885-023-10800-x
- By:
- Publication type:
- Article
4
Intratumoral heterogeneity in programmed death‐ligand 1 immunoreactivity is associated with variation in non‐small cell lung carcinoma histotype.
- Published in:
- Histopathology, 2020, v. 76, n. 3, p. 394, doi. 10.1111/his.13983
- By:
- Publication type:
- Article
5
Optimising Cancer Vaccine Design in Sarcoma.
- Published in:
- Cancers, 2019, v. 11, n. 1, p. 1, doi. 10.3390/cancers11010001
- By:
- Publication type:
- Article
6
Effect of targeted therapy and immunotherapy on advanced nonsmall‐cell lung cancer outcomes in the real world.
- Published in:
- Cancer Medicine, 2022, v. 11, n. 1, p. 86, doi. 10.1002/cam4.4427
- By:
- Publication type:
- Article
7
Observation as a treatment strategy for advanced renal cell carcinoma—a call for prospective validation.
- Published in:
- 2012
- By:
- Publication type:
- Opinion
8
Efficient Genotyping of KRAS Mutant Non-Small Cell Lung Cancer Using a Multiplexed Droplet Digital PCR Approach.
- Published in:
- PLoS ONE, 2015, v. 10, n. 9, p. 1, doi. 10.1371/journal.pone.0139074
- By:
- Publication type:
- Article
9
The efficacy of crizotinib in patients with ALK-positive nonsmall cell lung cancer.
- Published in:
- Therapeutic Advances in Respiratory Disease, 2015, v. 9, n. 3, p. 97, doi. 10.1177/1753465815577738
- By:
- Publication type:
- Article
10
Poor treatment outcomes with palliative gemcitabine and docetaxel chemotherapy in advanced and metastatic synovial sarcoma.
- Published in:
- 2018
- By:
- Publication type:
- journal article
11
Real-World Outcomes of Stage IV NSCLC with PD-L1 ≥ 50% Treated with First-Line Pembrolizumab: Uptake of Second-Line Systemic Therapy.
- Published in:
- Current Oncology, 2023, v. 30, n. 6, p. 5299, doi. 10.3390/curroncol30060402
- By:
- Publication type:
- Article